Pioglitazone inhibits growth of human retinoblastoma cells via regulation of NF-κB inflammation signals

References

• Robert J. Resistance to cytotoxic agents. Curr Opin Pharmacol 2001;1:353–7.
   PubMedGoogle Scholar
• Hanusova V, Skalova L, Kralova V, Matouskova P. Potential anti-cancer drugs commonly used for other indications. Curr Cancer Drug Targets 2015;15:35–52.
   PubMed Web of Science ®Google Scholar
• Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990;347:645–50.
   PubMed Web of Science ®Google Scholar
• Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med 2002;53:409–35.
   PubMed Web of Science ®Google Scholar
• Panigrahy D, Kaipainen A, Kieran MW, Huang S. PPARs: a double-edged sword in cancer therapy? PPAR Res 2008;2008:350351.
   PubMed Web of Science ®Google Scholar
• Ninomiya I, Yamazaki K, Oyama K, et al. Pioglitazone inhibits the proliferation and metastasis of human pancreatic cancer cells. Oncol Lett 2014;8:2709–14.
   PubMed Web of Science ®Google Scholar
• Takano S, Kubota T, Nishibori H, et al. Pioglitazone, a ligand for peroxisome proliferator-activated receptor-gamma acts as an inhibitor of colon cancer liver metastasis. Anticancer Res 2008;28:3593–9.
   PubMed Web of Science ®Google Scholar
• McCormick DL, Horn TL, Johnson WD, et al. Suppression of rat oral carcinogenesis by agonists of peroxisome proliferator activated receptor γ. PLoS One 2015;10:e0141849.
   Google Scholar
• Sasaki H, Tanahashi M, Yukiue H, et al. Decreased perioxisome proliferator-activated receptor gamma gene expression was correlated with poor prognosis in patients with lung cancer. Lung Cancer 2002;36:71–6.
   PubMed Web of Science ®Google Scholar
• Tsubouchi Y, Sano H, Kawahito Y, et al. Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis. Biochem Biophys Res Commun 2000;270:400–5.
   PubMed Web of Science ®Google Scholar
• Cerbone A, Toaldo C, Minelli R, et al. Rosiglitazone and AS601245 decrease cell adhesion and migration through modulation of specific gene expression in human colon cancer cells. PLoS One 2012;7:e40149.
   PubMed Web of Science ®Google Scholar
• Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 1971;68:820–3.
   PubMed Web of Science ®Google Scholar
• Dimaras H, Kimani K, Dimba EA, et al. Retinoblastoma. Lancet 2012;379:1436–46.
   PubMed Web of Science ®Google Scholar
• Wang J, Liu XH, Yang ZJ, et al. The effect of ROCK-1 activity change on the adhesive and invasive ability of Y79 retinoblastoma cells. BMC Cancer 2014;14:89.
   PubMed Web of Science ®Google Scholar
• Kim EJ, Park KS, Chung SY, et al. Peroxisome proliferator-activated receptor-gamma activator 15-deoxy-Delta12,14-prostaglandin J2 inhibits neuroblastoma cell growth through induction of apoptosis: association with extracellular signal-regulated kinase signal pathway. J Pharmacol Exp Ther 2003;307:505–17.
   PubMed Web of Science ®Google Scholar
• Blanquicett C, Roman J, Michael Hart C. Thiazolidinediones as anti-cancer agents. Cancer Ther 2008;6:25–34.
   PubMedGoogle Scholar
• Al-Mansouri LJ, Alokail MS. Molecular basis of breast cancer. Saudi Med J 2006;27:9–16.
   PubMed Web of Science ®Google Scholar
• Kitamura S, Miyazaki Y, Shinomura Y, et al. Peroxisome proliferator-activated receptor gamma induces growth arrest and differentiation markers of human colon cancer cells. Jpn J Cancer Res 1999;90:75–80.
   PubMedGoogle Scholar
• Cao LQ, Chen XL, Wang Q, et al. Upregulation of PTEN involved in rosiglitazone-induced apoptosis in human hepatocellular carcinoma cells. Acta Pharmacol Sin 2007;28:879–87.
   PubMed Web of Science ®Google Scholar
• Hirsch J, Johnson CL, Nelius T, et al. PEDF inhibits IL8 production in prostate cancer cells through PEDF receptor/phospholipase A2 and regulation of NFκB and PPARγ. Cytokine 2011;55:202–10.
   PubMed Web of Science ®Google Scholar
• Bo QF, Sun XM, Liu J, et al. Antitumor action of the peroxisome proliferator-activated receptor-γ agonist rosiglitazone in hepatocellular carcinoma. Oncol Lett 2015;10:1979–84.
   PubMed Web of Science ®Google Scholar
• Sun Y, Zheng B, Zhang XH, et al. PPAR-γ agonist stabilizes KLF4 protein via activating Akt signaling and reducing KLF4 ubiquitination. Biochem Biophys Res Commun 2014;443:382–8.
   PubMed Web of Science ®Google Scholar
• Tan BS, Kang O, Mai CW, et al. 6-Shogaol inhibits breast and colon cancer cell proliferation through activation of peroxisomal proliferator activated receptor γ (PPARγ). Cancer Lett 2013;336:127–39.
   PubMed Web of Science ®Google Scholar
• Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002;108:153–64.
   PubMed Web of Science ®Google Scholar
• Subramanian N, Navaneethakrishnan S, Biswas J, et al. RNAi mediated Tiam1 gene knockdown inhibits invasion of retinoblastoma. PLoS One 2013;8:e70422.
   Google Scholar
• Huan L, Bao C, Chen D, et al. MicroRNA-127-5p targets the biliverdin reductase B/nuclear factor-B pathway to suppress cell growth in hepatocellular carcinoma cells. Cancer Sci 2016;107:258–66.
   PubMed Web of Science ®Google Scholar
• Sengupta S, Krishnakumar S, Sharma T, et al. Histopathology of retinoblastoma: does standardization make a difference in reporting? Pediatr Blood Cancer 2013;60:336–7.
   PubMed Web of Science ®Google Scholar
• Hou Y, Moreau F, Chadee K. PPARgamma is an E3 ligase that induces the degradation of NFkappaB/p65. Nat Commun 2012;3:1300.
   PubMed Web of Science ®Google Scholar
• Karin M. NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol 2009;1:a000141.
   PubMed Web of Science ®Google Scholar
• Myant KB, Cammareri P, McGhee EJ, et al. ROS production and NF-kappaB activation triggered by RAC1 facilitate WNT-driven intestinal stem cell proliferation and colorectal cancer initiation. Cell Stem Cell 2013;12:761–73.
   PubMed Web of Science ®Google Scholar
• Hoesel B, Schmid JA. The complexity of NF-kappaB signaling in inflammation and cancer. Mol Cancer 2013;12:86.
   PubMed Web of Science ®Google Scholar
• Li Q, Withoff S, Verma IM. Inflammation-associated cancer: NF-kappaB is the lynchpin. Trends Immunol 2005;26:318–25.
   PubMed Web of Science ®Google Scholar
• Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006;441:431–6.
   PubMed Web of Science ®Google Scholar
• Brodowska K, Theodoropoulou S, Zu Hörste M, et al. Effects of metformin on retinoblastoma growth in vitro and in vivo. Int J Oncol 2014;45:2311–24.
   PubMed Web of Science ®Google Scholar
• Azoulay L, Yin H, Filion KB, et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ 2012;344:e3645.
   PubMed Web of Science ®Google Scholar
• Assiamira F, Lewis JD, Quesenberry CP, Jr, et al. Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care 2011;34:923–9.
   PubMed Web of Science ®Google Scholar
• Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 2011;34:916–22.
   PubMed Web of Science ®Google Scholar